Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4844 clinical trials
Featured trial
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the

hallucinations
  • 1270 views
  • 16 Mar, 2020
  • 68 locations
Featured trial
Genotypic Influences on Network Progression in Parkinson's Disease

increase in brain network activity over time (network progression rate) is faster in patients with GBA gene mutations.

positron emission tomography
movement disorder
antiparkinsonian agents
  • 2 views
  • 26 Jan, 2023
  • 1 location
Featured trial
A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease (Voice-PD)

The aim of this research program is to develop and validate a smartphone app-based digital measurement concept that: Objectively quantifies the severity of Parkinson's Disease (PD) related vocal and speech symptoms; Accurately and sensitively identifies vocal and speech abnormalities associated with the prodromal stage of PD.

Accepts healthy volunteers
  • 0 views
  • 24 Oct, 2022
  • 1 location
Featured trial
Subthalamic Nucleus Deep Brain Stimulation in Speech Study (SiSS)

Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) have unpredictable and varied speech outcomes after this treatment. Our research will prospectively document speech performance before, during and 6- and 12-months after STN-DBS in 80 surgically treated patients and compared with 40 non-surgical controls …

parkinsonism
levodopa
brain stimulation
cognitive impairment
  • 0 views
  • 04 Oct, 2022
  • 1 location
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

continues until disease progression or unacceptable toxicity (ie, not for a fixed number of courses). The primary endpoint of the study is progression-free survival (PFS) time according to RECIST 1.0; key

neutrophil count
adenocarcinoma of colon
adenocarcinoma
modified folfox6
growth factor
  • 7 views
  • 26 Feb, 2022
  • 1 location
  • 0 views
  • 24 Oct, 2022
  • 44 locations
  • 0 views
  • 27 Oct, 2022
  • 92 locations
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O'HAND)

in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional

  • 248 views
  • 13 Feb, 2022
  • 149 locations
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus (TN-22)

The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of

  • 694 views
  • 13 Feb, 2022
  • 51 locations
Pressure Injury Treatment by Intermittent Electrical Stimulation:

Multicentered randomized controlled study with adaptive design to evaluate if Intermittent Electrical Stimulation (IES) decreases progression and facilitates healing of pressure injuries for

  • 0 views
  • 10 May, 2022
  • 3 locations